<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584922</url>
  </required_header>
  <id_info>
    <org_study_id>13165</org_study_id>
    <nct_id>NCT00584922</nct_id>
  </id_info>
  <brief_title>Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation</brief_title>
  <official_title>Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively follow the next 200 patients who undergo
      catheter ablation of atrial fibrillation for symptoms and signs of esophageal injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to prospectively follow the next 200 patients who undergo
      catheter ablation of atrial fibrillation and endoscopy. If any signs of esophageal injury are
      seen on endoscopy the patients will be treated with omeprazole and sucralfate and they will
      have repeat endoscopy in two weeks. Patients who do not have any esophageal injury will be
      contacted by telephone in two weeks to be assessed for GI symptoms.

      Specific Aims: The specific aims of the study are to:

        1. Assess the incidence of visible transmural esophageal injury following extensive
           ablation in the posterior left atrium as measured by endoscopy1

        2. Assess whether early detection of esophageal injury by endoscopy and treatment will
           prevent development of more serious injury such as left atrial-esophageal fistula

        3. Identify predictors of esophageal injury. In particular, to assess if esophageal
           temperature rises during ablation correlate with development of esophageal injury and if
           the absence of esophageal temperature rise during ablation correlate with the absence of
           esophageal injury.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">March 11, 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Esophageal Injury as Assessed by Endoscopy</measure>
    <time_frame>1 month</time_frame>
    <description>Endoscopy results and clinical status at one month after endoscopy procedure.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">175</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>AF ablation group</arm_group_label>
    <description>Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopy in group I (all patients)</intervention_name>
    <description>Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.</description>
    <arm_group_label>AF ablation group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18-80 scheduled to undergo catheter ablation of atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years

          -  Scheduled to have catheter ablation of atrial fibrillation or left atrial
             macroreentrant tachycardia.

        Exclusion Criteria:

          -  Contraindication to endoscopy

          -  Pregnancy

          -  Prisoners

          -  Inability or unwillingness to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Beckman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OU Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <results_first_submitted>March 22, 2017</results_first_submitted>
  <results_first_submitted_qc>May 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2019</results_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal injury</keyword>
  <keyword>Catheter Ablation</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AF Ablation Group</title>
          <description>Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
Endoscopy in group I (all patients): Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AF Ablation Group</title>
          <description>Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
Endoscopy in group I (all patients): Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Esophageal Injury as Assessed by Endoscopy</title>
        <description>Endoscopy results and clinical status at one month after endoscopy procedure.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AF Ablation Group</title>
            <description>Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
Endoscopy in group I (all patients): Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Esophageal Injury as Assessed by Endoscopy</title>
          <description>Endoscopy results and clinical status at one month after endoscopy procedure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulcer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fistula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Endoscopy one day after ablation Clinical evaluation 1 month after ablation</time_frame>
      <desc>Adverse events were collected by:
endoscopy results
Telephone survey at one month</desc>
      <group_list>
        <group group_id="E1">
          <title>AF Ablation Group</title>
          <description>Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
Endoscopy in group I (all patients): Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophageal erythema</sub_title>
                <description>by endoscopy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Esophageal erosion</sub_title>
                <description>by endoscopy</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Esophageal Ulcer</sub_title>
                <description>By endoscopy</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sunny Po, MD, PhD</name_or_title>
      <organization>University of Oklahoma Health Science Center</organization>
      <phone>405-271-9696</phone>
      <email>Sunny-Po@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

